Whole-brain radiotherapy for brain metastases: evolution or revolution?
PD Brown, MS Ahluwalia, OH Khan… - Journal of Clinical …, 2018 - ascopubs.org
An estimated 20% of patients with cancer will develop brain metastases. Approximately
200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) …
200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) …
Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults
C Wilke, D Grosshans, J Duman, P Brown… - Neuro-oncology, 2018 - academic.oup.com
Radiotherapy is ubiquitous in the treatment of patients with both primary brain tumors as well
as disease which is metastatic to the brain. This therapy is not without cost, however, as …
as disease which is metastatic to the brain. This therapy is not without cost, however, as …
Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer
JF Teng, QB Mei, XG Zhou, Y Tang, R Xiong, WQ Qiu… - Cancers, 2020 - mdpi.com
Trillium tschonoskii Maxim (TTM), a traditional Chinese medicine, has been demonstrated to
have a potent anti-tumor effect. Recently, polyphyllin VI (PPVI), a main saponin isolated from …
have a potent anti-tumor effect. Recently, polyphyllin VI (PPVI), a main saponin isolated from …
Management of brain metastases in tyrosine kinase inhibitor–naïve epidermal growth factor receptor–mutant non–small-cell lung cancer: a retrospective multi …
WJ Magnuson, NH Lester-Coll, AJ Wu… - Journal of clinical …, 2017 - ascopubs.org
Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for …
growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for …
Polyphyllin VI, a saponin from Trillium tschonoskii Maxim. induces apoptotic and autophagic cell death via the ROS triggered mTOR signaling pathway in non-small …
JF Teng, DL Qin, QB Mei, WQ Qiu, R Pan… - Pharmacological …, 2019 - Elsevier
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.
Our previous studies have proven that Trillium tschonoskii Maxim.(TTM), a traditional …
Our previous studies have proven that Trillium tschonoskii Maxim.(TTM), a traditional …
Targeting EGFR in lung cancer: current standards and developments
A Díaz-Serrano, P Gella, E Jiménez, J Zugazagoitia… - Drugs, 2018 - Springer
Lung cancer is the second most common malignant tumor and the leading cause of cancer
death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …
death. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …
Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
H Wang, Z Wang, G Zhang, M Zhang, X Zhang… - Cancer …, 2020 - Wiley Online Library
Background A retrospective analysis verified the role of gene mutations in brain metastasis
in patients with non‐small cell lung cancer (NSCLC). Methods Data from 552 patients with …
in patients with non‐small cell lung cancer (NSCLC). Methods Data from 552 patients with …
[HTML][HTML] Brain metastases in oncogene-driven non-small cell lung cancer
M Nishino, K Soejima, T Mitsudomi - Translational Lung Cancer …, 2019 - ncbi.nlm.nih.gov
Molecular targeted therapies have significantly improved the treatment outcome of patients
with non-small cell lung cancer (NSCLC) harboring driver gene mutations such as receptor …
with non-small cell lung cancer (NSCLC) harboring driver gene mutations such as receptor …
Clinical value of upfront cranial radiation therapy in osimertinib-treated epidermal growth factor receptor–mutant non-small cell lung cancer with brain metastases
F Yu, J Ni, W Zeng, Y Zhou, T Guo, Y Zeng… - International Journal of …, 2021 - Elsevier
Purpose As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a …
inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a …
Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases
OBJECTIVE The object of this retrospective study was to investigate the impact of targeted
therapies on overall survival (OS), distant intracranial failure, local failure, and radiation …
therapies on overall survival (OS), distant intracranial failure, local failure, and radiation …